Precision medicine is an emerging approach for disease treatment and prevention that considers genetics, epigenetics, metabolism, environment, lifestyle, and diet of each individual patient with the final aim of individually tailoring the health care. Metabolomics can be pivotal to achieving this goal. Indeed, metabolites are the downstream output of the genome, the transcriptome, and the proteome, as well as the upstream input from all various external stimuli, and for these reasons the most proximal reports of any disease status or phenotype. Therefore, in the last years, metabolomics has provided unique insights into the underlying molecular mechanisms and metabolic impact of various pathophysiological conditions.
Pharmacometabolomics deals with the prediction of the outcome of a drug or xenobiotic intervention in a patient, based on his/her individual metabolite signature. Metabolomics may help in identifying subjects who are most likely to respond to treatments and those who may be at risk of suffering from harmful side effects. Consequently, this approach could significantly contribute to early-phase drug development as well as to precision medicine. The goal of this Research Topic is to collect high-quality scientific articles that highlight the importance of metabolomics application to pharmacological advancements in the field of respiratory diseases, aiming at the broader implementation of precision medicine.
This collection welcomes original metabolomics research articles reporting application in the field of respiratory diseases such as chronic diseases (i.e. asthma, chronic obstructive pulmonary disease, cystic fibrosis, lung cancer) as well as viral respiratory diseases (i.e. influenza viruses, respiratory syncytial virus, respiratory adenoviruses, coronaviruses). Systematic reviews or meta-analyses that critically discuss crucial innovations or applications in the field or seek to investigate areas of controversy within the literature will also be considered. Areas of interest could include, but are not limited to:
· Groundbreaking applications of metabolomics in pharmacology
· Drug and/or xenobiotic monitoring and biomarker discovery
· Pharmacometabolomics via LC-MS, NMR, and/or other techniques
· Development of novel metabolomic instrumental, analytical, and computational methods that are potentially transformative to patient health care
· Multi-omic and multi-platform studies
Precision medicine is an emerging approach for disease treatment and prevention that considers genetics, epigenetics, metabolism, environment, lifestyle, and diet of each individual patient with the final aim of individually tailoring the health care. Metabolomics can be pivotal to achieving this goal. Indeed, metabolites are the downstream output of the genome, the transcriptome, and the proteome, as well as the upstream input from all various external stimuli, and for these reasons the most proximal reports of any disease status or phenotype. Therefore, in the last years, metabolomics has provided unique insights into the underlying molecular mechanisms and metabolic impact of various pathophysiological conditions.
Pharmacometabolomics deals with the prediction of the outcome of a drug or xenobiotic intervention in a patient, based on his/her individual metabolite signature. Metabolomics may help in identifying subjects who are most likely to respond to treatments and those who may be at risk of suffering from harmful side effects. Consequently, this approach could significantly contribute to early-phase drug development as well as to precision medicine. The goal of this Research Topic is to collect high-quality scientific articles that highlight the importance of metabolomics application to pharmacological advancements in the field of respiratory diseases, aiming at the broader implementation of precision medicine.
This collection welcomes original metabolomics research articles reporting application in the field of respiratory diseases such as chronic diseases (i.e. asthma, chronic obstructive pulmonary disease, cystic fibrosis, lung cancer) as well as viral respiratory diseases (i.e. influenza viruses, respiratory syncytial virus, respiratory adenoviruses, coronaviruses). Systematic reviews or meta-analyses that critically discuss crucial innovations or applications in the field or seek to investigate areas of controversy within the literature will also be considered. Areas of interest could include, but are not limited to:
· Groundbreaking applications of metabolomics in pharmacology
· Drug and/or xenobiotic monitoring and biomarker discovery
· Pharmacometabolomics via LC-MS, NMR, and/or other techniques
· Development of novel metabolomic instrumental, analytical, and computational methods that are potentially transformative to patient health care
· Multi-omic and multi-platform studies
